
Microsoft sued by authors for allegedly using pirated books to train AI model
A group of prominent authors, including Pulitzer Prize winner Kai Bird and New Yorker writer Jia Tolentino, has filed a lawsuit against Microsoft, accusing the tech giant of illegally using pirated versions of their books to train its AI model known as 'Megatron.
' Filed in a New York federal court on June 25, the suit claims that Microsoft copied nearly 200,000 copyrighted works without permission to develop AI systems that mimic the authors' unique writing styles, themes, and voices. This marks another major legal challenge in the growing debate over AI training and copyright law.
Authors accuse Microsoft of
copyright infringement
The plaintiffs allege that Microsoft used a massive dataset of pirated digital books to train Megatron, a generative AI model designed to produce human-like text.
According to the complaint, the AI's ability to replicate the tone, syntax, and narrative patterns of copyrighted works demonstrates a clear violation of intellectual property rights. The authors argue that their creative output was exploited to build a product that competes with them in the marketplace, without their consent or compensation.
Lawsuit demands damages and a court injunction
The writers are seeking statutory damages of up to $150,000 per infringed work, along with a court order to block Microsoft from continuing its alleged unauthorised use of their materials.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Buy Brass Idols - Handmade Brass Statues for Home & Gifting
Luxeartisanship
Buy Now
Undo
While the exact number of infringed titles remains unclear, the plaintiffs claim that thousands of authors' works may have been used without licence or attribution. The case could set a precedent for how courts handle AI training involving copyrighted content.
Legal backdrop: A turning point in AI copyright battles
This lawsuit comes just one day after a California judge ruled that AI firm Anthropic may have made 'fair use' of copyrighted material in training but could still be liable for using pirated versions of books.
It was the first US decision to address the legality of using copyrighted texts in generative AI development. The Microsoft case adds further momentum to a wave of lawsuits from writers, artists, and media outlets challenging how their work is used by tech companies.
Microsoft yet to respond publicly
According to Reuters, Microsoft has not issued an official response to the allegations. A spokesperson for the company declined to comment when contacted by reporters.
Meanwhile, legal observers say this case will be closely watched for its implications on the future of AI development and intellectual property rights.
A growing challenge for the AI industry
Tech firms including Meta, OpenAI, and Anthropic have all faced similar legal scrutiny in recent time. The central argument from the companies is that using public data for AI training qualifies as 'fair use' under US copyright law. However, rights holders argue that this approach undermines creators' control and devalues their work. As AI models become increasingly sophisticated, courts should define clearer boundaries around what constitutes ethical and legal data usage.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
20 minutes ago
- Time of India
Altimmune's stock plummets over 60% as liver drug falls short in trial
Altimmune's stock (NASDAQ: ALT) plunged roughly 60–64% in pre-market trading today after it announced mixed results from its mid-stage (IMPACT Phase 2b) trial evaluating its liver drug, pemvidutide , for metabolic dysfunction-associated steatohepatitis (MASH). The drug showed promising results in reducing liver fat and achieving MASH resolution, but failed to deliver strong statistical evidence for fibrosis improvement—a key benchmark in this disease area. What is the current stock price of Altimmune? As of June 26, 2025 , Altimmune is trading at $7.71 per share . This price represents a significant pullback from its recent highs, though it remains above its 52-week low. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo Current price: $7.71 52-week high: $11.16 52-week low: $3.55 Market cap: Estimated between $558 million to $625 million Also Read: US stock futures rise: Dow, S&P 500, and Nasdaq edge higher as Nvidia, BlackBerry, and QuantumScape rally Did pemvidutide meet its primary endpoint? Yes. The trial hit its primary goal: resolution of MASH without worsening liver fibrosis. At 24 weeks: Live Events 59.1% of patients on the 1.2 mg dose saw MASH resolution 52.1% achieved resolution on the 1.8 mg dose Only 19.1% on placebo met this benchmark These results were statistically significant and well above expectations, positioning pemvidutide as a serious contender in the MASH space. Also Read: Intel layoffs 2025: Design engineers, software architects lose jobs - these key divisions are next What about weight loss and secondary benefits? Altimmune also highlighted significant weight loss among trial participants: 5.0% weight loss at 1.2 mg 6.2% at 1.8 mg , compared to 1.0% in placebo This positions pemvidutide alongside other GLP-1 class weight-loss drugs, a category currently generating high investor and consumer interest. Why did the stock crash despite positive results? The issue lies with the fibrosis endpoint. While there were improvements, the trial didn't reach statistical significance in its primary analysis of fibrosis reduction—a major goal in MASH treatment. Though an AI-assisted analysis showed 30.6% of patients had ≥60% reduction in fibrosis (vs. 8.2% placebo), it wasn't enough to reassure investors looking for definitive progress in this area. Are analysts still bullish on Altimmune? Yes, despite the sell-off, Wall Street remains optimistic about Altimmune's long-term prospects. The stock currently holds a "Strong Buy" rating from analysts. That suggests potential upside of nearly 190% from the current price level, assuming pemvidutide regains investor confidence in later trials. What are the short-term stock trends for ALT? Technically, ALT has been highly volatile and is currently trading in the mid-range of its 52-week band . Short-term charts show neutral-to-bearish signals , with some analysts recommending caution until the stock finds support or stabilizes. What is MASH treatment? MASH, short for Metabolic dysfunction-associated steatohepatitis, is the new name for what was previously called NASH (Non-Alcoholic Steatohepatitis). It's a serious form of fatty liver disease that occurs when fat builds up in the liver and causes inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, or even liver cancer. What's next for Altimmune and pemvidutide? Altimmune will hold an investor webcast to discuss results and plans to meet the FDA for an End-of-Phase 2 meeting by late 2025. A Phase 3 trial is still under consideration. FAQs: What caused Altimmune stock to crash after the MASH trial? The stock crashed after its MASH drug failed to show strong results in improving liver fibrosis. Is Altimmune still moving forward with pemvidutide? Yes, the company plans to meet the FDA and may start a Phase 3 trial.


Time of India
20 minutes ago
- Time of India
Invicta Diagnostic raises Rs 6 crore in pre-IPO round
Mumbai-based Invicta Diagnostic on Thursday said it has raised Rs 6 crore from marquee investors in its pre-IPO funding round. The funding round was led by Grobiz SME Opportunities Fund with participation from prominent angel investors, the company said in a statement. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Ingin Tahu Tentang Diagnosis Limfoma? Dapatkan Info Selengkapnya Limfoma Baca Undo Invicta Diagnostic provides a one-stop solution for pathology and radiology testing services , including imaging and clinical laboratory. It has seven diagnostic centres and one centralised laboratory across the Mumbai Metropolitan Region. It offers comprehensive radiology and pathology solutions under the brand name 'PC Diagnostics'.


Hindustan Times
21 minutes ago
- Hindustan Times
ChatGPT CEO Sam Altman is 'surprised' by how much people blindly trust it: 'AI hallucinates'
Are you among those who believe the AI boom to be a plague descending humanity into an irreversible descent? Or is the icon pinned on the homepage of your phone and arguably your most used app? ChatGPT Sam Altman is 'surprised' at how much people trust AI Either way, you'll want to read this one — either for the satisfaction a good old 'I told you so!' will get you, or, because this might be the PSA you NEED. And it comes straight from the horse's mouth. ChatGPT CEO Sam Altman spoke at the OpenAI Podcast earlier this month, and in no uncertain words, expressed genuine surprise at how much of their life people had tied into being dependent on the AI messenger. "People have a very high degree of trust in ChatGPT, which is interesting, because AI hallucinates. It should be the tech that you don't trust that much", he said, matter-of-factly. That being said, it's been a trial and error process for the CEO himself too. Sharing a personal anecdote, Sam revealed how when he turned a new parent, he found himself a little too logistically woven into the ChatGPT nexus as he made sense of his new role: "It was always on, helping me decide everything from nap routines to what to do about diaper rash", he said. "But I had to remind myself it doesn't always get it right", he added and that's what anybody who finds themselves on the same wavelength should ideally take note of. As a parting shot, Sam articulated on how dependence on and in the real world, is very necessary in making sure that the power remains vested in us: "We need societal guardrails. We're at the start of something powerful, and if we're not careful, trust will outpace reliability", he said. Running things through ChatGPT, asking it for help in maneuvering certain situations and other such instances are perfectly fine. However, it's best to take most of what comes up as suggestions and pointers instead of the final world. And just because it sounds human, doesn't in the least bit make it so. AI ethicist at the University of Toronto, Dr. Melissa Tran captures the dilemma well: "It speaks like a confident human. That alone makes people feel like it knows what it's talking about even when it doesn't". So what's your stance on ChatGPT now?